174 related articles for article (PubMed ID: 31043821)
1. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
[TBL] [Abstract][Full Text] [Related]
2. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
Lexchin J
BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers AJN; Regier DA; Peacock SJ
Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
Jenei K; Meyers DE
BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
[TBL] [Abstract][Full Text] [Related]
5. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
Berry SR; Hubay S; Soibelman H; Martin DK
BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
[TBL] [Abstract][Full Text] [Related]
6. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
[TBL] [Abstract][Full Text] [Related]
7. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
Naipaul RD; Mercer RE; Chan KKW; Yeung L; Forbes L; Gavura S
Curr Oncol; 2021 Feb; 28(2):1056-1066. PubMed ID: 33652898
[TBL] [Abstract][Full Text] [Related]
8. A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision.
Leung L; de Lemos ML; Kovacic L
J Oncol Pharm Pract; 2018 Dec; 24(8):584-598. PubMed ID: 28747103
[TBL] [Abstract][Full Text] [Related]
9. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
Morrell L; Wordsworth S; Fu H; Rees S; Barker R
BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
[TBL] [Abstract][Full Text] [Related]
10. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC
Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389
[TBL] [Abstract][Full Text] [Related]
11. What does meaningful look like? A qualitative study of patient engagement at the Pan-Canadian Oncology Drug Review: perspectives of reviewers and payers.
Rozmovits L; Mai H; Chambers A; Chan K
J Health Serv Res Policy; 2018 Apr; 23(2):72-79. PubMed ID: 29624087
[TBL] [Abstract][Full Text] [Related]
12. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
[TBL] [Abstract][Full Text] [Related]
13. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups.
Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW
Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233
[TBL] [Abstract][Full Text] [Related]
14. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
15. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
17. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
Lemieux J; Audet S
Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
[TBL] [Abstract][Full Text] [Related]
18. Value assessment of oncology drugs using a weighted criterion-based approach.
Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB
Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138
[TBL] [Abstract][Full Text] [Related]
19. An evaluation framework for funding drugs for rare diseases.
Winquist E; Bell CM; Clarke JT; Evans G; Martin J; Sabharwal M; Gadhok A; Stevenson H; Coyle D
Value Health; 2012; 15(6):982-6. PubMed ID: 22999151
[TBL] [Abstract][Full Text] [Related]
20. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
MacLeod TE; Harris AH; Mahal A
Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]